Pascale Tomasini

4.3k total citations · 1 hit paper
109 papers, 1.8k citations indexed

About

Pascale Tomasini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Pascale Tomasini has authored 109 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pulmonary and Respiratory Medicine, 70 papers in Oncology and 23 papers in Cancer Research. Recurrent topics in Pascale Tomasini's work include Lung Cancer Treatments and Mutations (68 papers), Lung Cancer Research Studies (36 papers) and Cancer Genomics and Diagnostics (22 papers). Pascale Tomasini is often cited by papers focused on Lung Cancer Treatments and Mutations (68 papers), Lung Cancer Research Studies (36 papers) and Cancer Genomics and Diagnostics (22 papers). Pascale Tomasini collaborates with scholars based in France, United States and Canada. Pascale Tomasini's co-authors include Fabrice Barlési, Laurent Greillier, Céline Mascaux, Kevin Jao, Natasha B. Leighl, Catherine Labbé, M. Souquet-Bressand, A. Jeanson, Mohamed Boucékine and S. Chaléat and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Analytical Chemistry.

In The Last Decade

Pascale Tomasini

97 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascale Tomasini France	22	1.1k	1.1k	465	425	143	109	1.8k
Penelope A. Bradbury Canada	29	1.1k 1.0×	1.1k 1.0×	604 1.3×	419 1.0×	150 1.0×	112	2.0k
Erika Rijavec Italy	24	1.1k 0.9×	707 0.6×	489 1.1×	420 1.0×	253 1.8×	93	1.7k
Christine Lydon United States	18	1.0k 0.9×	1.2k 1.1×	658 1.4×	435 1.0×	132 0.9×	30	1.8k
Antonio Galvano Italy	24	996 0.9×	800 0.7×	475 1.0×	540 1.3×	122 0.9×	96	1.8k
Jessica Menis Italy	21	1.2k 1.0×	1.1k 1.0×	381 0.8×	363 0.9×	120 0.8×	76	1.9k
Harpreet Singh United States	24	1.0k 0.9×	647 0.6×	495 1.1×	427 1.0×	178 1.2×	101	1.8k
Delphine Borchiellini France	22	986 0.9×	1.2k 1.0×	639 1.4×	458 1.1×	135 0.9×	89	1.8k
Alex Friedlaender Switzerland	28	1.5k 1.3×	1.1k 1.0×	711 1.5×	437 1.0×	263 1.8×	86	2.3k
Barbara Melosky Canada	28	1.3k 1.1×	1.1k 1.0×	388 0.8×	334 0.8×	102 0.7×	116	2.0k
Giulia Pasello Italy	23	1.1k 1.0×	1.1k 1.0×	510 1.1×	349 0.8×	155 1.1×	165	2.0k

Countries citing papers authored by Pascale Tomasini

Since Specialization

Citations

This map shows the geographic impact of Pascale Tomasini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascale Tomasini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascale Tomasini more than expected).

Fields of papers citing papers by Pascale Tomasini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascale Tomasini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascale Tomasini. The network helps show where Pascale Tomasini may publish in the future.

Co-authorship network of co-authors of Pascale Tomasini

This figure shows the co-authorship network connecting the top 25 collaborators of Pascale Tomasini. A scholar is included among the top collaborators of Pascale Tomasini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascale Tomasini. Pascale Tomasini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gautschi, Oliver, Keunchil Park, Benjamin Solomon, et al.. (2025). Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 43(15). 1758–1764. 4 indexed citations

Salas, Sébastien, Frédéric Ginot, Laurent Greillier, et al.. (2024). 137P Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker. Annals of Oncology. 35. S270–S270. 1 indexed citations

Tomasini, Pascale, Claire Cropet, A. Jeanson, et al.. (2024). LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways. Annals of Oncology. 35. S1242–S1242. 3 indexed citations

Boucékine, Mohamed, Johan Pluvy, Pascale Tomasini, et al.. (2024). Lack of Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer in Real Life, with the Emergence of Immunotherapy. Cancers. 16(23). 4122–4122.

Dall’Olio, Filippo Gustavo, Bastien Job, Stefan Michiels, et al.. (2024). Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.. Journal of Clinical Oncology. 42(16_suppl). 2632–2632. 1 indexed citations

Thomas, P., Alex Fourdrain, Geoffrey Brioude, et al.. (2024). A pilot quality improvement initiative for lymph node dissection during lung cancer surgery. European Journal of Cardio-Thoracic Surgery. 66(6).

Dall’Olio, Filippo Gustavo, Damien Vasseur, Maryam Karimi, et al.. (2023). Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.. Journal of Clinical Oncology. 41(16_suppl). 2516–2516.

Horinouchi, Hidehito, Jonathan W. Goldman, Byoung Chul Cho, et al.. (2023). O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC. Annals of Oncology. 34. S1387–S1387. 1 indexed citations

Denis, Marc G., Christine Sagan, Audrey Vallée, et al.. (2023). 1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients. Annals of Oncology. 34. S781–S781. 1 indexed citations

10.

Macagno, Nicolas, Laurent Greillier, M.‐A. Richard, et al.. (2023). Étude de cohorte évaluant la toxicité cutanée des anticorps bispécifiques anti-EGFR et anti-MET seuls ou en association aux inhibiteurs d’EGFR. 3(8). A145–A145.

11.

Soo, Ross A., Jean‐François Martini, Anthonie J. van der Wekken, et al.. (2023). Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC. Journal of Thoracic Oncology. 18(11). 1568–1580. 22 indexed citations

12.

Drilon, Alexander, Vivek Subbiah, Oliver Gautschi, et al.. (2022). Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 41(2). 385–394. 119 indexed citations breakdown →

13.

Mazieres, J., Pascale Tomasini, Amélie Lusque, et al.. (2020). 1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S826–S827. 10 indexed citations

14.

Bermudez, Julien, Céline Mascaux, Youssef Trigui, et al.. (2019). Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer. Journal of Cancer Therapy. 10(8). 692–707.

15.

Tomasini, Pascale, et al.. (2019). First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer. Translational Cancer Research. 8(7). 2514–2516. 5 indexed citations

16.

Bancaud, Aurélien, Audrey Didelot, Fréderic Fina, et al.. (2018). BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA. Analytical Chemistry. 90(6). 3766–3774. 31 indexed citations

17.

Jeanson, A., et al.. (2018). Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. Expert Review of Anticancer Therapy. 19(1). 11–17. 7 indexed citations

18.

Tomasini, Pascale, et al.. (2016). Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. The Oncologist. 21(12). 1450–1460. 96 indexed citations

19.

Tomasini, Pascale, et al.. (2016). Adrenal surgery for oligometastatic tumors improves survival in selected cases. Journal of Visceral Surgery. 154(2). 87–91. 4 indexed citations

20.

Tomasini, Pascale, et al.. (2013). Solitary cystic mediastinal lymphangioma. European Respiratory Review. 22(127). 91–93. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact